× Current Issue Archive Submit Article
Conflicts of Interest Copyright and Access Open access policy Editorial Policies Peer Review Policy Privacy Statement Publishing Ethics
Editor in chief Associate Editors Advisory Board International Editors
Contact Us About Us Aim & Scope Abstracting And Indexing Author Guidelines Join As Editor

Review of treatment management for patients with Epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer


Mathialagan A., Visnumukkala T., Kademane K., Agus I.W.3, Mathialagan B., Palaniyappan T

Abstract

Introduction: Nowadays, lung cancer is the most popular cause of cancer-related deaths all around the world. However, the new progressions in determining specific oncogenes with driver mutations, such as the Epidermal Growth Factor Receptor (EGFR) gene has ameliorated the prognosis of non-small-cell lung cancer formation. Studies on these bio-markers have targeted the pathways in which drugs act as specific inhibitors to cancer progression. Tyrosine Kinase Inhibitors (TKIs) against EGFR, such as Erlotinib and Gefitinib, have been able to provide considerable progression free survival (PFS) for patients by stopping these tumour boosting properties in non-small-cell lung cancers. Unfortunately, persistent resistance mechanisms have made these agents ineffective in their treatment. To overcome resistance, new multiple agents were developed, but the treat of resistance still looms over each new advance in EGFR inhibition based targeted therapy. This article reviews the 1st and 2nd Generation EGFR inhibition, common resistance mechanisms, 3rd Generation EGFR inhibitor and subsequent treatment option.




Contact Meral


Meral Publications
www.meralpublisher.com

Davutpasa / Zeytinburnu 34087
Istanbul
Turkey

Email: [email protected]
Tell: +905344998991